For drugs where PBMs previously extracted large rebates to bring net cost to an acceptable level, the MFP may effectively compress the rebate that manufacturers need to offer for commercial formulary placement in non-Medicare channels, since the MFP provides a market benchmark for net pricing
Pharmacological approaches include DPP-4 inhibitors, which prevent GLP-1 degradation, and GLP-1 receptor agonists, both approved by NICE for type 2 diabetes management in appropriate patients according to treatment guidelines
The bold new logo conveys stability, trust, and the brands reputation for sustainable health outcomes, the company stated, signaling a move toward a more clinical, evidence-based identity
NA-931 is interesting because it is not just another GLP-1 variation
[23] For weight management patients, decreased potency typically results in reduced appetite suppression and slower gastric emptying effects, potentially leading to weight regain or plateau